SiRNA inhibiting PPFIA1 gene expression, and its application
Patent Information
- Authority / Receiving Office
- CN · China
- Patent Type
- Patents(China)
- Current Assignee / Owner
- 广州安镝声生物医药科技有限公司
- Publication Date
- 2014-08-06
Smart Images
Figure 1 Figure 2 Figure 3
Abstract
Description
technical field
[0001] The invention relates to an siRNA, in particular to an siRNA for inhibiting the expression of PPFIA1 gene and its application. Background technique
[0002] Chronic myelogenous leukemia (CML) is a malignant proliferative disease of hematopoietic stem cells mainly characterized by myelogenous hyperplasia, and its characteristic cytogenetic marker is Ph chromosome t(9;22)(q34;q11 ). P210BCR-ABL fusion protein is the product of Ph chromosome, has strong tyrosine kinase activity, and is closely related to the occurrence of CML. Its production can lead to the continuous phosphorylation of a series of signaling proteins downstream of it, thereby causing hematopoietic stem cells Pathophysiological changes such as malignant proliferation, anti-apoptosis, and adhesion function defects occur. Epidemiological surveys show that the incidence of CML among leukemia in my country is 1 / 10 5 , second only to Jili and Jilin, ranking third, showing a clear increasing ...